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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effectiveness of EEG neurofeedback as treatment for inhibition and updating problems in children facing neurodevelop-
mental challenges.
B A C K G R O U N D
Neurodevelopmental disorders encompass a range of conditions,
each with cognitive challenges that become apparent during child-
hood. Historically, these have been conceptualised as various dis-
tinct disorders on the basis of clinical phenotype and the classifica-
tion of symptom clusters in the Diagnostic and Statistical Manual
of Mental Disorders (DSM) Fourth Edition Text Revision (DSM-
IV-TR) or Fifth Edition (DSM-5), or in the International Clas-
sification of Diseases, 10th Revision (ICD-10) (APA 2000; APA
2013; WHO 1993). Neurodevelopmental disorders include con-
ditions such as intellectual disability; autism; Asperger syndrome;
fetal alcohol spectrum disorder (FAS); fragile X syndrome; Down
syndrome; and attention deficit hyperactivity disorder (ADHD)
(Bishop 2008; Bishop 2010). However, existing classifications for
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neurodevelopmental disorders are not mutually exclusive, nor are
these taxonomic systems intended to speak to causation - this
presents a significant limitation when treatment options are con-
sidered.
Recent development of the Research Domain Criteria (RDoC)
has encouraged scientists to undertake transdiagnostic reanalysis
of disorders in the interests of identifying shared causal pathways
and consequently informing more effective prophylactic or cura-
tive responses, or both (Coghill 2015). At the same time, emerg-
ing literature on neural circuitry is illuminating development of
circuits that mediate core complex cognitive processes and be-
haviours in ways that cut across these diagnostic groups (Glahn
2016). Rather than distinct disorders, it is hypothesised that differ-
ent phenotypes emerge as a result of the complex interplay of envi-
ronment and biology within these neural circuits (Cuthbert 2010;
Rutter 2010). For example, common cognitive functions that are
implicated in a range of mental illnesses as well as in intellec-
tual and behavioural disorders include reward response, emotional
regulation, extinction, working memory, and response inhibition
(Insel 2010a; Leckman 2010). In cognitive terms, these processes
are summarised under the umbrella term ‘executive functions’ or
cognitive control (Davidson 2006; Garvey 2016). They form the
point of transdiagnostic intersect for several neurodevelopmental
disorders (Doyle 2015; Insel 2010b).
Inhibition and updating dominate the executive function litera-
ture and are the cognitive functions that have received the most
attention as key functions of executive control (Miyake 2000; St.
Clair-Thompson 2006). As such, they form a secure conceptual
platform for this review. Inhibition refers to the capacity to in-
hibit task-irrelevant distractors and to resolve conflict in pursuit
of a particular goal (Barkley 1997; Hughes 2002; Miyake 2000;
Padmanabhan 2015; Sergeant 2000). Inhibition is implicated in
tasks such as the Stroop or Flanker task. Updating refers to the
functioning of working memory and is implicated in coding of
new information and, accordingly, in revising the information that
is currently held in working memory. This function is targeted by
tasks such as letter or digit memory and the Rey Auditory Ver-
bal Learning Task (Kane 2003; Miyake 2000). Electroencephalo-
graphic (EEG) neurofeedback training provided to target inhibi-
tion and updating is described in the literature.
In sum, EEG neurofeedback treatment for neurodevelopmental
disorders targeting the circuitry for inhibition or updating provides
hope for prevention and remediation and will serve as the focus
of this review.
Description of the condition
A considerable proportion of the population is affected by neu-
rodevelopmental disorders including the following.
1. Autism. It is estimated that 1 in 160 children worldwide
has a diagnosis of autism, which equates to more than 7.6
million disability-adjusted life-years and 0.3% of the global
burden of disease (WHO 2013; WHO 2016a).
2. ADHD. It is estimated that 39 million people are affected
by ADHD globally (WHO 2013). American reports suggest that
approximately 11% of children between 4 and 17 years of age
(6.4 million) are affected (Visser 2014). Australian figures
suggest that 7.4% (298,000) of 4- to 17-year-olds who had a
mental disorder between 2013 and 2014 suffered from ADHD
(Lawrence 2015). Between 5 and 14 years of age, an estimated
3.4% of total years (1800 years) is lived in ill health or with
disability, making ADHD the eighth leading cause of non-fatal
loss of health for children in this age group in Australia (AIHW
2011).
3. Intellectual disabilities. An international meta-analysis in
29 countries indicated that, on average, 10.37 individuals among
every 1000 people are affected (Maulik 2011). This is the
seventh leading cause of non-fatal loss of health for children
between birth and five years of age in Australia, with an
estimated 4.3% of total years (700 years) lived in ill health or
with disability (AIHW 2011).
4. Down syndrome, FAS disorder, and fragile X syndrome.
These conditions have received little attention in statistical
accounts; therefore, epidemiological data on these specific
intellectual disorders are limited to prevalence rates. The
incidence rate for Down syndrome is estimated to be around 1 in
1000 to 1 in 1100 live births worldwide (WHO 2016b).
Western Australia reported estimates of FAS disorder of 0.4 per
1000 live births for the total population between 2000 and 2004
(Bower 2007). Roozen indicated that between 1990 and 2005
the reported occurence of FAS disorder in Canada, Italy, and the
United States was in between 30.52 and 47.13 per 1000, and, in
South Africa, the prevalence of FAS disorder is particularly high,
at 113.22 per 1000 (Roozen 2016). In the absence of life
expectancy data for fragile X syndrome, and given the strong
genetic component involved in development of this disorder,
prevalence rates are expected to be the same across all age groups
(Brown 2010). Leykin reported that numbers of Australian
persons with fragile X syndrome were expected to range between
1362 and 4309 for a full mutation with intellectual disability,
and Brown anticipated numbers of 13,466 and 87,137 with a
permutation (Brown 2010; Leykin 2009). Crawford estimated
that 1 in 3717 individuals of European descent is affected by this
condition (Crawford 2002). Youings projected that 1 in 5530
persons in the United Kingdom would receive a diagnosis of
fragile X syndrome, and, most recently, Coffee anticipated that
fragile X syndrome would occur in 1 in 5161 males in the
United States (Coffee 2009; Youings 2000). In sum,
neurodevelopmental disorders exact a significant toll on
individuals, families, and communities. Gaining an
understanding of causal pathways with a view toward prevention
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or remediation should be seen as a priority.
Difficulties with cognitive control are evident in the neurocog-
nitive profiles of many individuals with different neurodevelop-
mental disorders and are implicated in the behavioural and emo-
tional presentation of affected children (Happé 2006; Pennington
1996). For example, problems related to inhibition and updat-
ing are present to varying degrees. The neurocognitive profiles of
children with fragile X syndrome and ADHDmost often indicate
problems with inhibitory control, which overlap with clinical fea-
tures of impulsivity and hyperactivity (Bari 2013; Happé 2006;
Hooper 2008; Knox 2012; Oosterlaan 2005). Difficulties with
updating are implicated in Down syndrome, fragile X syndrome,
and intellectual disability, all of which have been associated with
limited ability to hold, manipulate, and process incoming infor-
mation (Daunhauer 2014; Hartman 2010; Hooper 2008).
Executive functioning, the central mechanism required for cogni-
tive control, refers to the ability of the cognitive system to co-ordi-
nate internal processes (e.g. perceptual selection and maintenance
of contextual information) in pursuit of performance of specific
tasks (e.g. reading a book) (Botvinick 2001). Although phenotypic
presentations of difficulties in this area can be diverse, their impact
on functioning generally aggregates and worsens as an individual
gets older (Goldstein 2010;Masten 2005). Thus, when treatments
for executive functioning challenges are considered, patient age is
critical.
Executive functions develop rapidly during childhood (from about
the age of six years) and adolescence (e.g. Anderson 2002). Not
only does executive control typically improve during this time,
but the nature of these functions is more fully differentiated
(Brydges 2012; Brydges 2014a; Shing 2010). The growing neu-
roplasticity literature informs us that integral to the maturation
of a child’s nervous system are sensitive (but not necessarily crit-
ical) periods for development (Davis 2009; Happé 2014; Heim
2012; Knudsen 2004; Newport 2001; Perani 2003; Wachs 2014;
Weber-Fox 1996). During these sensitive periods, the brain is par-
ticularly susceptible to change through experience, with poten-
tial for diminished remediation in adulthood. Therefore, consid-
ering treatment possibilities, such as EEG neurofeedback, during
emerging stages of executive functions provides hope for reme-
diating long-term dysfunction (Sonuga-Barke 2010). This devel-
opmental period accounts for the choice of age groups included
in the present review. We will focus on children and adolescents
between 6 and 18 years of age. As executive dysfunction plays a
role in various disorders, review authors will not discriminate be-
tween disorders. Instead, we will focus on core executive functions
targeted through EEG neurofeedback, specifically, inhibition and
updating.
Description of the intervention
Cognitive-behavioural therapy, behavioural intervention, medi-
cal treatment, or a combination of at least two of these is cur-
rently employed to manage symptoms of neurodevelopmental
disorders (Ageranioti-Bélanger 2012; Fabiano 2009; Hsia 2014;
Moskowitz 2011; Murawski 2015; Narzisi 2014; Reichow 2011;
Scheifes 2013;Weston 2016). Conclusions regarding the effective-
ness of non-invasive symptomatic treatment approaches are often
limited by methodological weaknesses, such as lack of method-
ological rigour or lack of randomisation during group allocation,
and future research is needed to further evaluate treatment op-
tions (Ozonoff 1998; Reid 2015; Walters 2016). The current al-
ternative to non-invasive approaches is pharmacological interven-
tion. The pharmacological treatment pathway serves as a popular
means of symptom control, particularly for children with ADHD
(Banaschewski 2006; Faraone 2010; Scheifes 2013). Although
pharmacological interventions may be deemed a moderately ef-
fective treatment option, side effects (e.g. headaches, dizziness, re-
duced appetite, growth restriction), lack of certainty around po-
tential long-term risks, reappearance of symptoms after discontin-
uation of treatment, and non-response tomedication have sparked
the search for non-invasive long-term treatments that can be pro-
vided without negative consequences (Graham 2011; Heinrich
2007; Jensen 2007; Murray 2008).
Technical advances have seen the development of EEG neuro-
feedback as a promising, non-pharmacological mode of interven-
tion that can be used to help train, prevent or remediate partic-
ipants’ cognitive impairment at the source. EEG neurofeedback
is commonly conceptualised as computer game-based training of
awareness or control of cognitive state that can be achieved by
providing participants with real-time feedback on their own brain
states (Figure 1). It is thought that participants can learn tomodify
or control targeted brain-state activity, inducing neural plasticity,
which leads to improved self-regulation in daily activities.
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Figure 1. Neurofeedback intervention loop. This figure is adapted from Bagdasaryan and Le Van Quyen. It
depicts a simplified overview of neurofeedback that is delivered via electroencephalography (EEG)
(Bagdasaryan 2013). During the neurofeedback session, the individual’s brain signal is acquired through the
EEG equipment (A, B). The software processes the incoming brain signal and provides information about the
degree of alignment between the participant’s real-time brain activity and predetermined training goal
parameters (C, D). This information is presented to the participant as visual or auditory feedback in real time,
to continuously update the participant about modulation of his or her own brain activity (E; Bagdasaryan 2013;
Huster 2014).
EEG neurofeedback is not dependent on complex verbal instruc-
tions; therefore, this brain-training intervention can be effectively
implemented cross-culturally and in groups with language and
communication impairment. It is designed to be embedded in a
game format, which offers face validity as a treatment for chil-
dren. Currently, neither implementation of this approach in the
community nor training of healthcare providers is monitored by
an accredited organising body. Instead, implementation of EEG
neurofeedback is based on the personal preferences of providers
and consumers, which makes a systematic review of the evidence
base for this treatment a critical task.
EEG neurofeedback training comprises a range of elements. A
fundamental technical component of this intervention is the tech-
nology that is used to monitor the degree of alignment between
the participant’s brain activity and the pre-set goal parameter. Var-
ious brain-imaging techniques have been utilised for the inter-
vention, such as near-infrared spectroscopy (NIRS), functional
magnetic resonance imaging (fMRI), and electroencephalography
(EEG) (Egner 2001;Marx 2015; Scharnowski 2015). Experimen-
tal research to appraise various brain-imaging techniques is ongo-
ing; however, to date, no one technique has been identified as the
superior method for obtaining neurofeedback, nor is compelling
evidence available to support the use of one technique over an-
other. Therefore, we argue that to get the most accurate picture
of changes in brain activity, such as those required in a micro-
analysis of learning, a measure that can capture the most fine-
grained changes in milliseconds rather than seconds is preferable
(Sauseng 2008). Because it offers the highest temporal resolution
of all known techniques, EEG is the only technology that meets
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this criterion. Additionally, EEG is less costly and is more widely
used than alternatives (Figure 2). Its use is also more feasible than,
for example, fMRI when healthcare providers are working with
children, as the experience of being inside an MRI machine can
be unsettling and may disrupt optimal task completion.
Figure 2. Publication rates between 2006 and 2016 of journal articles examining EEG-, fMRI-, and NIRS-
neurofeedback, as indexed by Scopus.FootnotesEEG: electroencephalogram; fMRI: functional magnetic
resonance imaging; NIRS: near-infrared spectroscopy.
EEG is a non-invasive method that is used to measure the brain’s
electrical activity along the scalp via sensors or electrodes. During
setup of EEG neurofeedback, these electrodes are placed on the
head of the participant, and training goal parameters define fea-
tures of the EEG signal that are to be trained (i.e. EEG frequency);
the number of electrodes; the placement location of electrodes on
the scalp; and the number, duration, and frequency of sessions
(e.g. to decrease theta/alpha activity and increase beta activity, one
electrode at Cz for 12 sessions overall, split into three 45-minute
sessions per week; to increase sensorimotor rhythm and suppress
theta activity, individualised training at, for example, C3 and C4,
for 30 sessions overall, split into two 20-minute sessions per week;
and to increase sensorimotor rhythm and suppress theta activity,
electrode placement at C4 for 40 sessions overall, split into 20
meetings of two 60-minute sessions each with a short break in
between (Arnold 2013; Lansbergen 2011; Perreau-Linck 2010)).
Once EEG neurofeedback equipment is set up, the participant’s
neural variability is recorded and analysed in real time, and the
degree of alignment between set parameters and the person’s neu-
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ral activity is communicated in the form of visual or auditory
feedback. Visual feedback may consist of a blurry picture of an
animated character. Only when the participant’s ongoing neu-
ral variability matches goal parameters would the picture become
clear. Alternative visual feedback may be received in the form of
virtual reality tasks, animated games, waveforms, or graphs (e.g.
Linden 1996). Auditory feedbackmay comprise tones that change
in volume, pitch, or duration as recorded activity fluctuates (Egner
2002).
The elaborate setup of the intervention poses interesting chal-
lenges for comparison or control groups in EEG neurofeedback
research. As the technology is integral to EEG neurofeedback, the
most rigourous and the only form of placebo for which blinding is
possible is sham EEG neurofeedback. During sham EEG neuro-
feedback, the participant receives feedback unrelated to his or her
own performance but based on pre-recorded or artificial EEG ac-
tivity. Apart from the technical elements that make it challenging
to find a placebo or carry out blinding, participants unsuccessfully
attempt to learn to modulate their (fictitious) neural activity, of-
ten resulting in poor compliance or frustration. Therefore, rather
than subjecting participants to a blinding trial, EEG neurofeed-
back research frequently implements alternative comparators such
as conventional treatments (i.e. active, non-invasive control trials,
for example, behavioural management interventions) and wait-
list controls, by which participants wait for their active treatment
intervention (Sonuga-Barke 2013).
Uncertainty in the literature pertains to the measurable effect of
EEG neurofeedback, as well as to effects of technology, target fre-
quency, electrode location, feedback type, number of sessions, and
session duration on the efficacy of the intervention. Each of these
intervention components forms a critical part of the intervention.
In theory, any changes in the composition of these parts can influ-
ence the efficacy of EEG neurofeedback and may constitute dis-
tinct therapeutic approaches. In the absence of an evidence base
for EEG neurofeedback, clinical practice currently operates on the
basis of literature that has produced favourable EEG neurofeed-
back outcomes in the past (e.g. Arnold 2013; Lubar 1995a). Each
component needs further research to explore its influence on the
intervention process. With a growing number of EEG neurofeed-
back studies and approaches, it is not clear which frequency, elec-
trode location, number of sessions, technology, or feedback type
provides the best EEG neurofeedback therapy for children with
executive functioning problems. As a starting point, we will look
at the current literature and will investigate the fundamental ef-
fectiveness of EEG neurofeedback.
How the intervention might work
Traditionally, researchers have conceptualised the neurofeedback
loop as a learning process, which follows behavioural learning
mechanisms of operant conditioning. Operant conditioning stud-
ies (e.g. Schedules of Reinforcement) have shown that targeted
participant behaviour can be regulated by providing positive rein-
forcement immediately after the targeted behaviour occurs (Ferster
1957). It is of great importance that the relationship between the
behaviour and the reinforcement is clear to the learner. As such,
the timing of presentation of the reinforcer is crucial, as even small
delays (as little as a second) can decrease the strength of the as-
sociation between the reinforcer and the target behaviour that is
to be reinforced (Skinner 1958). Use of EEG in the neurofeed-
back paradigm has enabled researchers to seek more immediate
and more secure associations via measurable aspects of behaviours
and reinforcers, such as by targeting the specific oscillations that
underlie clinical symptoms like impulsivity or hyperactivity as the
independent variable (Gevensleben 2012). It is therefore conceiv-
able that the capacity for EEG neurofeedback to provide sub-
second feedback may make it especially efficient as an approach
to behaviour modification and brain plasticity, as compared with
mental regulation unassisted by feedback (Bai 2014; Beatty 1974).
Nevertheless, it should be noted that this potential advantage of
high temporal resolution of EEG over other neurofeedback tech-
niques has not been demonstrated.
Progressing technology has enabled researchers to seek clues in
an attempt to describe EEG neurofeedback mechanisms from a
biological viewpoint. As mentioned earlier, during EEG neuro-
feedback, the participant is provided with feedback about differ-
ences between target parameters and their actual neural activity. In
theory, through this feedback, the participant can learn to mod-
ulate brain activity towards the target parameter. Fundamental to
this step is the idea that, during training, the participant learns to
memorise the neural or behavioural state at the time of the reward,
which facilitates reproduction of this same pattern in the future.
Currently, the mechanisms that underpin this learning process
have not been fully illuminated. However, principles of neuroplas-
ticity may provide further clues to the causal pathway.
Neuroplasticity refers to the unique ability of the brain to grow
neurons and to alter neural connections in response to experi-
ences (Siegel 2010). Imaging studies have indicated, for exam-
ple, how training in activities such as music, exercise, or medita-
tion can have a lasting impact on brain structure or function, or
both (Vance 2010; Zatorre 2013). This finding highlights the fact
that repeated, activity-dependent experiences can have a lasting
impact on the brain (Ganguly 2013). Converging evidence sug-
gests that reinforcing a particular oscillatory pattern through EEG
neurofeedback training increases the likelihood that the same pat-
tern will be reproduced more easily in the future (Lubar 1995b;
Ros 2010). For the beta rhythm, for example, this effect is robust
enough to be detected up to three years after EEG neurofeed-
back training (Engelbregt 2016). This supports the fundamental
premise of EEG neurofeedback that the brain can be conditioned
to exhibit certain oscillatory patterns.
Theoretically, this phenomenon might be explained by a com-
bination of previously established plasticity mechanisms, such as
associative and homeostatic forms (Ros 2014). The principle of
associative (i.e. Hebbian) plasticity suggests that “synapses that fire
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together, wire together and synapses that fire apart, wire apart”
(Knoblauch 2012).Neurophysiological evidence indicates that the
amplitude of EEG oscillations is augmented by the number of
neurons (or synaptic potentials) (Musall 2014). Therefore, with
repeated training, the connections between neuron populations
that are amplified or synchronised to create a particular oscillatory
pattern would strengthen, facilitating generation of this pattern
in the future. Common to all these theories is the hypothesis that
modification of neural circuitry is possible and is likely to result
in observable behavioural changes.
At a more technical level, during EEG neurofeedback, electrodes
that are placed on the scalp measure the synchronised, rhythmi-
cal fluctuations of local field potentials of groups of neurons, also
known as neural oscillations. These oscillations arise from the exci-
tatory postsynaptic potentials (EPSPs) of large groups of neurons,
resulting in a measurable EEG signal at scalp level (Nunez 2000).
Synchronised oscillatory activities are associated with cognitive
abilities such as inhibition (for a review, see Klimesch), updating of
working memory, and temporary maintenance of information in
working memory, which suggests that neural oscillations are a fun-
damental functional mechanism in cortical computation (Deiber
2007; Klimesch 2006; Sauseng 2010).
Why it is important to do this review
Executive functions play a critical role in everyday life. Perfor-
mance of complex tasks, academic achievement, and later success
in life are mediated by the development of executive functioning
(Garavan 1999; Miyake 2000; St. Clair-Thompson 2006). EEG
neurofeedback treatment provides hope for prevention and reme-
diation of difficulties in the area of executive functioning for chil-
dren with neurodevelopmental disorders. New EEG neurofeed-
back protocols are continuously being tested to determine what
most effectively reduces or remediates executive functioning dif-
ficulties in neurodevelopmental disorders such as inhibition and
updating (e.g. Kouijzer 2009). However, commercial use of EEG
neurofeedback is currently outpacing the evidence base. The eco-
nomic cost of this intervention is high for parents, but patient
desperation is also high. A history of poorly researched interven-
tions for children (e.g. studies by Bishop and Stephenson) has en-
couraged the profession to take greater accountability in establish-
ing the effectiveness of new treatments as a matter of priority and
professional ethics (Bishop 2007; Stephenson 2008). Use of EEG
neurofeedback as an intervention for children with neurodevel-
opmental problems has reached just such a critical juncture. It is
imperative that the evidence base for these interventions is now
put to the test.
This systematic review is the first of its kind and therefore will
make a unique contribution to the EEG neurofeedback literature.
It is preliminary to any further investigations of the cost-effective-
ness or feasibility of this intervention. If the effectiveness of EEG
neurofeedback is supported by this review, it is conceivable that
additional research will be conducted to identify its applicability
to other mental health conditions or age groups.
O B J E C T I V E S
To assess the effectiveness of EEG neurofeedback as treatment for
inhibition and updating problems in children facing neurodevel-
opmental challenges.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) (i.e. random allocation of
participants to treatment, control, or follow-up groups) and quasi-
RCTs (i.e. allocation of participants to intervention or control
groups via date of birth, etc.).
Types of participants
Children or adolescents, or both, aged 6 to 18 years with execu-
tive functioning difficulties in the domains of inhibition and up-
dating. We will identify these neurodevelopmental challenges in
the literature via the clinical diagnosis of a neurodevelopmental
disorder such as intellectual disability, autism spectrum disorder
(ASD), FAS disorder, fragile X syndrome, Down syndrome, and
ADHD, as specified by the Diagnostic and Statistical Manual of
Mental Disorders (DSM) Fourth Edition Text Revision (DSM-IV-
TR) or Fifth Edition (DSM-5), or by the International Classifica-
tion of Diseases, 10th Revision (ICD-10) (APA 2000; APA 2013;
WHO 1993).
Excluded participants
We will exclude participants with severe brain damage, epilepsy,
Tourette’s syndrome, or any condition in which the focus of neu-
rofeedback intervention is not specific to executive functions (e.g.
to remediate damage, seizures, or tics), as well as participants with
non-neurodevelopmental comorbidities (e.g. depression).
We will include participants with neurodevelopmental challenges
as well as those with other mental health problems, as long as data
provided for participants with neurodevelopmental challenges can
be considered separately.
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Types of interventions
EEGneurofeedback (also referred to as EEGbiofeedback), regard-
less of protocol (target frequency), feedback type (visual vs aural),
and session number and duration, used as treatment for improv-
ing levels of inhibition and updating (or both) in children with
neurodevelopmental challenges. We will include studies adminis-
tering EEG neurofeedback in combination with another interven-
tion only when the cointervention is administered to both groups.
For reasons outlined earlier in this protocol, control groups will
include sham feedback (i.e. feedback that is unrelated to the partic-
ipant’s neural activity at the time of intervention administration),
treatment as usual (e.g. behavioural management intervention),
and wait-list control (see Description of the intervention).
Types of outcome measures
Primary outcomes
1. Changes in participant EEG profiles (e.g. event-related
potential (ERP), specifically, N2 for inhibition and P3 for
updating (Brydges 2014b;Donchin 1988: Luck 2014;Polich
2007))
2. Changes in inhibition (e.g. Stroop Color and Word Test:
Children’s Version) and changes in updating (e.g. Rey Auditory
Verbal Learning Test) (Golden 2002; Schmidt 1996)
3. Adverse effects (e.g. Pittburgh Side Effects Rating Scale)
(Pelham 1999) (It is important to note that we will consider only
outcome assessments for which the outcome assessor was
blinded.)
Secondary outcomes
1. Changes in behavioural performance (e.g. hyperactivity and
impulsivity, as measured by self-report measures such as Conners-
3 (Conners 2011)) (Again, we will consider only outcome
assessments for which the outcome assessor was blinded.)
Search methods for identification of studies
Electronic searches
We will search the electronic databases and trials registers listed
below, and will not limit our searches by language, date, or pub-
lication type.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; current issue) in the Cochrane Library, which
includes the Cochrane Developmental, Psychosocial and
Learning Problems Specialised Register.
2. MEDLINE Ovid (1946 onwards).
3. MEDLINE In-Process and Other Non-Indexed Citations
Ovid (current issue).
4. MEDLINE Epub Ahead of Print Ovid (current issue).
5. Embase Ovid (1974 onwards).
6. CINAHL Plus EBSCOhost (Cumulative Index to Nursing
and Allied Health Literature; 1937 onwards).
7. PsycINFO Ovid (1806 onwards).
8. Science Citation Index - Expanded Web of Science (SCI-
EXPANDED; 1970 onwards).
9. Social Sciences Citation Index Web of Science (SSCI; 1970
onwards).
10. Conference Proceedings Citation Index - Science Web of
Science (CPCI-S; 1990 onwards).
11. Conference Proceedings Citation Index - Social Science &
Humanities Web of Science (CPCI-SS&H; 1990 onwards).
12. Cochrane Database of Systematic Reviews (CDSR; current
issue), part of the Cochrane Library.
13. Database of Abstracts of Reviews of Effects (DARE; current
issue), part of the Cochrane Library.
14. Epistemonikos (www.epistemonikos.org/nl/
advanced search).
15. WorldCat (OCLC) (www.worldcat.org/default.jsp).
16. ClinicalTrials.gov (www.clinicaltrials.gov).
17. World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP; apps.who.int/trialsearch).
We will use the strategy provided in Appendix 1 to search MED-
LINE, and we will adapt it appropriately for searches of the other
databases. When papers are published in a language other than




We will search the websites listed below for unpublished studies
in this field.
1. The Association for Applied Psychophysiology and
Biofeedback, Inc. (aapb.org).
2. The Biofeedback Federation of Europe (bfe.org).
3. EEG Spectrum International (eegspectrum.com/ADHD-
ADD).
4. International Society for Neurofeedback and Research (
isnr.org).
5. Applied Neuroscience Society of Australasia (
appliedneuroscience.org.au).
Reference lists
We will search the reference lists of all eligible studies included in
this review for additional relevant studies that meet our inclusion
criteria (see Criteria for considering studies for this review).
8EEG neurofeedback for executive functions in children with neurodevelopmental challenges (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Data collection and analysis
Selection of studies
Two review authors (JL and SB)will individually examine the titles
and abstracts of records yielded by the search and will assess them
against the inclusion criteria of this review (Criteria for considering
studies for this review). For all studies that meet the inclusion cri-
teria, or for which more information is needed to assess eligibility,
we will obtain the full-text reports, and both review authors (JL
and SB) will separately reassess these studies against the inclusion
criteria. For full-text reports that are not written in the English
language, or for data that are not available in the article, we will
contact study authors for further information, to help us ascertain
the eligibility of these studies for inclusion in the present review.
We will record reasons for inclusion or exclusion of all studies sep-
arately, and JL and SB will discuss discrepancies between views.
When conflicting views cannot be reconciled, these review authors
will consult the entire research team until a consensus is reached.
Before any studies are selected, we will pilot-test application of
the eligibility criteria. Finally, for maximum transparency during
this selection process, we will complete a PRISMA flow diagram
(Liberati 2009).
Data extraction and management
Two review authors (JL and SB) will independently extract and
enter the following data from each study onto an electronic spread-
sheet specifically designed for this Cochrane Review: participant
details (age, gender, executive function problems); intervention
details (number of sessions, session duration, follow-up, electrode
location(s), frequency parameter, aural or visual feedback mode);
study location; type of study (RCT, quasi-RCT); intervention pro-
cedures (treatment allocation, blinding); type of control group
(sham feedback, treatment as usual, wait-list control); and out-
come measure data. Before any data are extracted, we will pilot
test the application of spreadsheet categories, to ensure that rel-
evant and comprehensive data are collected. We will resolve dis-
agreements amongst ourselves that might occur during the data
extraction process. When conflicting views cannot be reconciled,
we will consult the entire research team until a consensus decision
is reached.
Assessment of risk of bias in included studies
Two review authors (JL and SB) will independently assess the risk
of bias of each included study, using theCochrane ’Risk of bias’ tool
(Higgins 2017). We will assess each study as having low, high, or
unclear risk of bias in relation to each of the ’Risk of bias’ domains
described below. JL and SB will record each rating separately and
will discuss discrepancies between views. When conflicting views
cannot be reconciled, we will consult the entire research team until
a consensus agreement is reached.
Cochrane ’Risk of bias’ tool
The domains described below form the ’Risk of bias’ assessments
for RCTs and quasi-RCTs.
Sequence generation
We will describe the method used in each study to generate the
participant allocation sequence and will assess whether this se-
quence should have produced comparable participant groups.
Review authors’ judgement: Is the participant allocation sequence
truly random, and what is the resulting risk of allocation bias to
experimental or control groups?
1. Low risk of bias: Study authors described the random
component in the allocation sequence of participants (e.g.
computer random number generator, random number table).
2. High risk of bias: Study authors described a non-random
component in the allocation sequence of participants (e.g.
allocation by date of birth or by judgement of the investigator).
3. Unclear risk of bias: The process of randomisation was not
described in sufficient detail to permit a judgement of low or
high risk of bias.
Allocation concealment
We will describe the measures that were used to conceal the allo-
cation process from participants and from investigators and will
determine whether this allocation to a particular group or training
schedule could have been foreseen before, or during, participation
by participants or investigators.
Review authors’ judgement: Is the participant allocation sequence
truly concealed, and what is the resulting risk of allocation bias
due to inadequate concealment?
1. Low risk of bias: The allocation procedure was adequately
concealed from participants and investigators (e.g. telephone
allocation).
2. High risk of bias: Participants or investigators could have
foreseen their allocation (e.g. when allocation was based on the
judgement of the clinician or on the date of birth of participants).
3. Unclear risk of bias: The allocation process was not
described in sufficient detail to permit a judgement of low or
high risk of bias.
Blinding of participants and personnel
We will describe all modes of blinding participants and staff from
any knowledge of the intervention that a participant received.
Review authors’ judgement: Are participants and personnel ade-
quately blinded from any knowledge of the type of intervention
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that participants received, and what is the resulting risk of perfor-
mance bias?
1. Low risk of bias: Lack of blinding (no blinding or
incomplete blinding) is present, but it is clear that this lack of
blinding is unlikely to influence the outcome; or participants and
personnel have been blinded, and it is unlikely that this blinding
has been interrupted.
2. High risk of bias: Lack of blinding (no blinding or
incomplete blinding) is present, and outcomes are likely to have
been influenced by lack of blinding; or participants and
personnel have been blinded, but it is likely that this blinding
has been interrupted, which has influenced the outcome.
3. Unclear risk of bias: The blinding process was not described
in sufficient detail to permit the judgement of low or high risk of
bias, or this outcome was not addressed in the study. Owing to
the learning component in EEG neurofeedback (see Description
of the intervention), we expect that most studies will fall into this
category.
Blinding of outcome assessment
Wewill describe all modes of blinding outcome assessors from any
knowledge of the intervention that a participant received.
Review authors’ judgement: Are outcome assessors adequately
blinded from any knowledge of the type of intervention that par-
ticipants received, and what is the resulting risk of detection bias?
1. Low risk of bias: The outcome assessment was not blinded,
but it is clear that this lack of blinding is unlikely to influence the
outcome measurement; or the outcome assessment has been
blinded, and it is unlikely that this blinding has been
interrupted, which has influenced outcome measurements.
2. High risk of bias: The outcome assessment was not blinded,
and outcomes are likely to have been influenced by the lack of
blinding, or the outcome assessment has been blinded, and it is
likely that this blinding has been interrupted, which has
influenced outcome measurements.
3. Unclear risk of bias: The blinding process was not described
in sufficient detail to permit the judgement of low or high risk of
bias, or this outcome was not addressed in the study. Owing to
the learning component in EEG neurofeedback (see Description
of the intervention), we expect that most studies will fall into this
category.
Incomplete outcome data
We will describe the completeness of outcome data, including
information on participant attrition, exclusions, re-inclusions for
analyses, and participant numbers for each intervention group, as
well as any withdrawals from study groups.
Review authors’ judgement: Are incomplete data handled ade-
quately, and what is the resulting risk of attrition bias?
1. Low risk of bias: There is no indication of missing data; if
data are missing, the same numbers of data points are missing
across intervention groups; the data have been imputed suitably;
or reasons for the missing data are unlikely to have influenced
the outcome.
2. High risk of bias: Uneven numbers of data points are
missing across intervention groups; data have been imputed
through an unsuitable approach; or reasons for missing data are
likely to have influenced the outcome.
3. Unclear risk of bias: Study authors did not provide
sufficient information that permits a judgement of low or high
risk of bias (e.g. no reasons for missing data provided), or this
outcome was not addressed in the study.
Selective reporting
To assess any reporting bias, we will examine whether all prespec-
ified outcomes have been reported. When this is not the case, we
will contact researchers to ask for non-reported findings.
Review authors’ judgement: Are there indications of selective out-
come reporting, and what is the resulting risk of reporting bias?
1. Low risk of bias: Study protocol is available, and outcomes
prespecified in the protocol have been reported; when the
protocol is not available, it is clear that all expected outcomes
have been reported.
2. High risk of bias: Not all of the outcomes prespecified in
the protocol were reported; measurements were used that were
not prespecified; outcomes were reported that were not
prespecified; reporting of outcomes was incomplete; or study
authors failed to include results for a particular outcome.
3. Unclear risk of bias: Study authors did not provide
sufficient information to permit a judgement of low or high risk
of bias. It is expected that most studies will fall into this category.
Allegiance bias
We will report any concerns of allegiance bias not otherwise cov-
ered by above-mentioned components of the ’Risk of bias’ tool.
Currently, no consensus has been reached on what constitutes an
effective measurement of allegiance bias. The procedure most of-
ten used to document and evaluate this type of bias was developed
byGaffan and colleagues (Gaffan 1995). However, in line with the
critique provided by Leykin and colleagues, we will focus on eval-
uation of the treatment protocol by its developers or, in this case,
on sponsorship by neurofeedback equipment owners, to measure
high, low, or unclear risk of allegiance bias (Leykin 2009).
1. Low risk of bias: no evidence that study authors developed
the protocol; study was not sponsored by neurofeedback
equipment owners.
2. High risk of bias: evidence that study authors developed the
protocol; study was sponsored by neurofeedback equipment
owners.
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3. Unclear risk of bias: information provided points towards
allegiance bias, but insufficient details prevent a judgement of
whether low or high risk of bias is present; evidence of this bias is
insufficient.
Measures of treatment effect
Continuous data
For continuous data, we will calculate the mean difference (MD),
when possible (i.e. when the same outcome variables were assessed
via the same measurement scale). When investigators assessed the
same outcome variables through differentmodes of data collection
(i.e. different scales, various scoring methods), we will calculate
the standardised mean difference (SMD). We will present both
the MD and the SMD with 95% confidence intervals (CIs).
Dichotomous data
For dichotomous data, we will compute the risk ratio (RR) for
each outcome and the 95% CI to describe the probability that a
particular outcome is going to occur.
Unit of analysis issues
Cluster-randomised trials
To our knowledge, no EEG neurofeedback studies have ran-
domised groups or clusters of participants, rather than individuals;
therefore, we do not expect to find any cluster-randomised trials
during our search. Should cluster-randomised trials become avail-
able in the future, we will assume that researchers have adjusted
for clustering in their results. For trials that have not previously
adjusted for clustering, we will attempt to calculate an estimate
of the intracluster correlation coefficient (ICC) by using the for-
mula provided in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). If we are unable to calculate the
ICC (owing to lack of information), we will request further infor-
mation from study authors or will attempt to calculate the ICC
using data from comparable studies or available resources. We will
examine the impact of variation in ICCs via a Sensitivity analysis
and will discuss outcomes in the Discussion section of the review.
Cross-over trials
We do not anticipate identifying any cross-over trials. However,
if we do, we will use data from the first period only, given the
possibility of a carry-over effect, and lack of available information
concerning the time taken for any intervention effects to fade or
’wash out’.
Studies with multiple interventions
We will combine all EEG groups and will conduct a simple, pair-
wise comparison with all control groups. For participants who
continue to receive medication, we will consider data only if par-
ticipants in both intervention and control groups continue to re-
ceive medication.Wewill conduct a sensitivity analysis to examine
the potential effects of differences in participants’ medication or
dosage, or both, on trial results (see Sensitivity analysis).
Multiple reports
When multiple reports describe the same study, we will take extra
care to ensure that only independent findings are reported. If it
is unclear whether reports include independent findings, we will
contact the report authors to ask for clarification.
Dealing with missing data
We will record attrition and missing outcome data for each study
and will contact study authors to request missing outcome data.
When study authors do not provide data for missing summary
statistics (e.g. standard deviations), we will base our calculations
on other reported outcomes, when possible. When study authors
do not provide data for missing specified outcomes, we will at-
tempt to conduct an intention-to-treat (ITT) analysis by includ-
ing participants randomised into a trial, irrespective of the group.
If an ITT analysis is not possible, we will conduct an available case
analysis using only participants whose outcome data are known.
We will examine the impact of missing data on the main analyses
via a Sensitivity analysis and will discuss outcomes in the Discus-
sion section of the review.
Assessment of heterogeneity
We will assess clinical and methodological heterogeneity by com-
paring the effects of distribution of key participant traits (e.g. dis-
tribution of sex, age, severity of executive functioning difficulties),
protocol factors (e.g. target frequency, electrode location, feedback
type, number of sessions, session duration), and trial factors (e.g.
randomisation) on the efficacy of the intervention. We will em-
ploy forest plots to identify any statistical heterogeneity (overlap
of CIs) and will quantify this by computing I2 and Chi2 statistics
(Deeks 2011). Although I2 of 50% is a reasonable indication of
heterogeneity, substantial heterogeneity will be clearly exemplified
by I2 of 65% (Section 9.5.2; Deeks 2011). The P value for the
Chi2 test must be less than 0.10. We will employ the Tau2 statistic
as a measure of between-study variability.
In the event of very high heterogeneity, we will identify studies
that are contributing to high heterogeneity and will exclude them.
If exclusion does not successfully remove the heterogeneity, wewill
not present outcomes of meta-analyses for this variable. We will
transparently record all actions and reasons for exclusion.
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Assessment of reporting biases
Before we include any studies, we will assess risk of allocation, de-
tection, performance, attrition, and reporting biases, as outlined
in the Assessment of risk of bias in included studies section above.
Additionally, when we include more than 10 studies, we will pre-
pare funnel plots to assess publication bias.We will visually inspect
these plots for skewness. When we find evidence of an asymmet-
rical funnel plot, we will apply Egger’s test (Egger 1997).
Data synthesis
To conduct the meta-analysis, we will pool outcome data through
Review Manager 5 (RevMan 5) (Review Manager 2014). Owing
to the nature of our study design, we will consider the likelihood
of heterogeneity in our data as high (e.g. data from varying EEG
neurofeedback protocols, participants with different disorders and
from different study designs).
Given the high probability of significant heterogeneity in our re-
sults, we will apply a random-effects model. We will conduct
subgroup analyses to systematically investigate heterogeneity (see
Subgroup analysis and investigation of heterogeneity).
’Summary of findings’
We will create a ’Summary of findings’ table using a combina-
tion of RevMan 5 (Review Manager 2014) and GRADEprofiler
(GRADEpro; GRADEpro GDT 2015). In this table, we will
present effects of EEG neurofeedback (1) on underlying ERPs of
executive function performance, (2) on executive function perfor-
mance as measured by psychometric tests, (3) in relation to overall
well-being of participants with adverse effects recorded, and (4) on
behavioural performance. Additionally, we will include the num-
ber of participants and a rating of the quality of evidence based on
GRADE criteria derived using GRADEpro (GRADEpro GDT
2015; Guyatt 2006; Schünemann 2006). Two review authors (JL
and SB) will independently rate the quality of evidence according
to one of four levels (high, moderate, low, or very low). For ex-
ample, we will rate the quality of evidence from a RCT as high;
however, presence of risk of bias (e.g. design limitations, limita-
tions in the implementation of studies that are likely to introduce
bias), indirectness of evidence (e.g. indirect effects on the popu-
lation, intervention or control groups, or outcomes), imprecision
(e.g. wide CIs due to small sample sizes), inconsistency of results
(e.g. unexplained heterogeneity), and/or reporting bias (e.g. pub-
lication bias; failure to report outcomes) may lower the GRADE
rating. Both review authors will make notes to guide their judge-
ments to ensure a transparent rating procedure.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses are observational in nature, and any conclu-
sions drawn are intended only to highlight potential areas of fu-
ture research (Deeks 2011). When sufficient outcome data are
available, we will carry out subgroup analyses and investigations of
heterogeneity for each outcome (see Types of outcome measures),
with consideration of the following points.
1. Investigation of the effectiveness of EEG neurofeedback as a
function of frequency, session number, session duration,
electrode location, or feedback type.
2. Investigation of the effectiveness of EEG neurofeedback as a
function of the control group against which it is compared.
3. Investigation of the effectiveness of EEG neurofeedback as a
function of the childhood disorder, as defined by diagnostic
criteria (DSM-IV-TR; DSM-5; ICD-10) (APA 2000; APA
2013; WHO 1993).
4. Investigation of the effectiveness of EEG neurofeedback as a
function of age.
5. Investigation of the interaction between intervention
factors (e.g. session numbers) and dropout rates.
Sensitivity analysis
Our goal is to draw robust conclusions regarding the questions that
we ask in this review. When methodological choices of individual
studies or trial analyses might compromise the robustness of our
conclusions, we will conduct sensitivity analyses. Specifically, we
anticipate that we will be able to conduct sensitivity analyses for
the situations listed below.
1. Comparison of variable findings from RCTs and quasi-
RCTs.
2. Studies with high or unclear risk of bias as indicated by the
’Risk of bias’ assessment.
3. Studies with concurrent psychopharmacological treatment.
4. Variation in ICCs for analyses pertaining to cluster-
randomised controlled trials.
5. Studies with missing data.
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A P P E N D I C E S
Appendix 1. Ovid MEDLINE search strategy
1 Neurofeedback/
2 Biofeedback, Psychology/
3 (neurofeedback or neuro-feedback).tw,kf.
4 (biofeedback or bio-feedback).tw,kf.
5 or/1-4
6 Electroencephalography/
7 (electroencephalograph$ or electro-encephalograph$ or EEG).tw,kf.
8 or/6-7
9 Feedback/
10 (feedback$ or feed-back$).tw,kf.
11 or/9-10
12 8 and 11
13 5 or 12
14 neurodevelopmental disorders/ (651)
15 ((neurodevelopment$ or neuro-development$) adj3 (disorder$ or disab$ or challeng$ or condition$)).tw,kf.
16 child development disorders/
17 developmental disabilities/
18 (developmental$ adj3 (disab$ or disorder$ or impair$)).tw,kf.
19 exp child development disorders, pervasive/
20 autis$.tw,kf.
21 asperger$.tw,kf.
22 exp “Attention Deficit and Disruptive Behavior Disorders”/
23 attention deficit$.tw,kf.
24 (hyperactiv$ or hyper-activ$).tw,kf.
25 impulsiv$.tw,kf.
26 (ADHD or ADDH or “AD/HD” or TDAH).tw,kf.
27 intellectual disability/
28 (intellectual$ adj3 (disab$ or disorder$ or impair$)).tw,kf.
29 (mental$ adj3 (disab$ or impair$ or handicap$ or retard$)).tw,kf.
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33 Fetal Alcohol Spectrum Disorders/
34 F?etal Alcohol.tw,kf.
35 Fragile X Syndrome/
36 (FRAXE or FRAXA).tw,kf.
37 “Fragile X”.tw,kf.
38 or/14-37
39 13 and 38
C O N T R I B U T I O N S O F A U T H O R S
JKL (guarantor) drafted the protocol with feedback from all other review authors.
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